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Background: Microdeletions of 14q22q23 have been associated with eye abnormalities and pituitary defects. Other
phenotypic features in deletion carriers including hearing loss and response to growth hormone therapy are less
well recognized. We studied genotype and phenotype of three newly identified children with 14q22q23 deletions,
two girls and one boy with bilateral anophthalmia, and compared them with previously published deletion patients
and individuals with intragenic defects in genes residing in the region.
Results: The three deletions were de novo and ranged in size between 5.8 and 8.9 Mb. All three children lacked
one copy of the OTX2 gene and in one of them the deletion involved also the BMP4 gene. All three patients
presented partial conductive hearing loss which tended to improve with age. Analysis of endocrine and growth
phenotypes showed undetectable anterior pituitary, growth hormone deficiency and progressive growth
retardation in all three patients. Growth hormone therapy led to partial catch-up growth in two of the three
patients but just prevented further height loss in the third.
Conclusions: The pituitary hypoplasia, growth hormone deficiency and growth retardation associated with
14q22q23 microdeletions are very remarkable, and the latter appears to have an atypical response to growth
hormone therapy in some of the cases.
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The morphogenesis of midline brain structures, eyes,
optic nerves and optic tracts is governed by a cascade of
transcription factors including SOX2, OTX2 and BMP4
[1]. Congenital anophthalmia, which is among the most
severe consequences of defects in this cascade, is often ac-
companied by pituitary dysfunction and growth failure
due to growth hormone (GH) deficiency [2-6]. Mutations
in SOX2 are the most common cause of anophthalmia,* Correspondence: zdenek.sedlacek@lfmotol.cuni.cz
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The co-occurrence of eye malformations and GH defi-
ciency is the highest (30%) in patients with OTX2 muta-
tions [3]. BMP4 defects can induce a similar brain and
ocular phenotype [6,7]. Mutations ranging from single nu-
cleotide substitutions to cytogenetically visible deletions
have been reported in OTX2 and BMP4, which are both
located in 14q22q23. We identified three unrelated pa-
tients with anophthalmia, partial hearing loss and pituitary
defects due to microdeletions of this region. This gave us
a unique opportunity to study not only the ocular pheno-
types which are well associated with these rare genetic de-
fects, but also other phenotypic features which are less
well characterized.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Facial photographs of the patients and their growth characteristics. (a) Patient 1 at the age of 6 months; (b) Patient 2 at the age
of 7 months; (c) Patient 3 at the age of 22 months; (d) Development of body length with the onset of GH administration indicated by arrows.




The girl (Figure 1a) was born to healthy parents of Mali
origin at 38 weeks of gestation by Caesarean section
because of abnormal fetal cardiac rhythm. Her birth
weight, length and head circumference (HC) were
3,110 g (50th centile), 51 cm (75th centile), and 35.5 cm
(75th centile), respectively. She showed bilateral anoph-
thalmia. Brain magnetic resonance imaging (MRI) de-
tected hypoplastic orbits, and absent optic nerves and
optic chiasm. The anterior pituitary was undetectable,
the posterior pituitary was ectopic with hypoplasia of
the pituitary stalk, and the sella was small and flat. She
had high forehead, microretrognathia, high arched pal-
ate, large ears, persistent hypotonia and right postaxial
polydactyly. Cardiac examination revealed a systolic
murmur and a perimembranous interventricular septal
defect of 3 mm. Skeletal radiography and external
genitalia were normal.
After birth, provoked otoacustic emissions were abnor-
mal on the left side. Auditory evoked potentials at 3 years
of age found a 60 dB threshold hearing in both ears. Be-
cause of persistent middle ear effusion, tympanostomic
tubes were inserted, but had to be removed due to chronic
otorrhea.
A very low serum IGF-I (9 μg/l) and cortisol (<10 nmol/
l) levels at 10 days of life suggested GH deficiency and a
cortisol function defect (confirmed by ACTH stimulation
test). The levels of other pituitary hormones were
normal (TSH 3.48 mUI/l, T4 17.8 pmol/l). The growth of
Patient 1 progressively deteriorated from −2.4 SD (60 cm)
at 6 months to −3.5 SD (71 cm) at 1.6 years and to −4.9
SD (75.5 cm) at 2.7 years of age (Figure 1d). GH therapy
at a dose of 35 μg/kg/day initiated at the age of 2.7 years
led to an improved growth rate and stepwise
normalization of circulating IGF-I (4, 11 and 135 μg/l at
the onset and after 3 and 12 months of therapy, respec-
tively; normal age-specific serum IGF-I range is 51–
218 μg/l).Patient 2
The girl (Figure 1b) was born to healthy Czech parents
in the 41st week of gestation with a weight of 3,500 g
(50th centile), length of 52 cm (75th centile), and HC of
33 cm (10th centile). Bilateral anophthalmia and relative
microcephaly were noted at birth. Brain MRI revealed
absence of optic nerves, optic chiasm and optic tracts.
The sella was flat, the pituitary stalk and posterior pituit-
ary were present and normally located, but the anterior
pituitary was undetectable. The patient showed pro-
found hypotonia and very large, low-set dysplastic ears,
high prominent forehead, high frontal hairline, and wide
nose with horizontal nostrils, but no cardiac or genital
defects. Radiography revealed the presence of 13 pairs of
ribs and unpent arcs of vertebral corpus Th1.
Investigation of otoacustic emissions was not success-
ful in the newborn. At 6 months of age she had normal
hearing at the left side and moderate conductive hearing
loss at the right side. Stenotic Eustachian tubes likely led
to decreased pressure in the middle ear cavity. The hear-
ing loss tended to improve with age.
Initially, the growth of the patient was normal. How-
ever, it started to decelerate to −0.8 SD (70 cm) at
10 months, −1.4 SD (76.3 cm) at 1.4 years and −1.8 SD
(79 cm) at 1.8 years of age (Figure 1d). Endocrine assess-
ment revealed GH deficiency (3.53 ug/l following insulin-
induced hypoglycemia at 17 months of age) and IGF-I
deficiency (11 ug/l; −1.79 SD) but normal other pituitary
functions (TSH 1.19 mIU/l, fT4 12.2 pmol/l, FSH 8.9 IU/l,
LH 0.9 IU/l, cortisol 555 nmol/l, prolactin 4.7 ug/l). GH
therapy at a dose of 25 μg/kg/day was initiated at the age
of 1.8 years. It improved the growth rate and the serum
IGF-I level (5, 75 and 116 μg/l at the onset, 12 and
24 months of therapy, respectively) but did not lead to
catch-up growth (99 cm at 4 years, i.e. -1.5 SD, Figure 1d).
Patient 3
The boy (Figure 1c) was born to healthy Czech parents
in the 37th week of gestation by Caesarean section due
to intrauterine growth retardation with a weight of
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for the gestational age), bilateral anophthalmia and
marked hypotonia. Brain MRI revealed absent optic chi-
asm; however, extraocular muscles were preserved. Simi-
larly to Patient 2, the sella was flat, the pituitary stalk
and posterior pituitary were present and normally
located, but the anterior pituitary was undetectable. Pa-
tient 3 showed mesocephaly with prominent narrow
forehead, a small narrow face and a wide nasal bridge. He
had no apparent morphological ear abnormalities and no
cardiac, spinal, abdominal, or genital defects. His bilateral
testicular retention required surgical management.
In the neonatal period, the investigation of otoacustic
emissions was unsuccessful. At the age of 3 months he
showed mild hearing loss of the right ear and medium
hearing loss of the left ear. Despite the tympanometry
was normal, the hearing loss was apparently conductive
due to stenotic ear canals. Also in this patient hearing
gradually improved with age.
Intrauterine growth retardation was followed by severe
postnatal growth failure: at the age of 7 weeks the boy had
a length of 48.4 cm (−3.7 SD), and weight of 3,010 g, and
his growth had further deteriorated (Figure 1d). He suffered
from GH deficiency (1.79 ug/l following clonidine stimula-
tion at 2.3 years of age) and IGF-I deficiency (2 ug/l). Other
pituitary functions were apparently normal (TSH 2.75
mIU/l, fT4 11.8 pmol/l, FSH 0.48 IU/l, LH 0.07 IU/l, corti-
sol 201 nmol/l, prolactin 5.7 ug/l); however, the bilateral
testicular retention might be suggestive of a gonadotropinFigure 2 Schematic representation of the 14q22q23 region affected b
as thick hatched bars, the deletions overlapping OTX2 and/or BMP4 in pub
are not shown. Protein-coding genes are indicated by black rectangles (OT
megabase scale are also included.deficiency. GH therapy at a dose of 25 μg/kg/day was initi-
ated at the age of 2.3 years. His height velocity on therapy
was atypical, with only a moderate increase within the
first year of GH administration but a marked increase
thereafter (92.0 cm at 4.1 years, i. e. -3.17 SD, Figure 1d).
Serum IGF-I levels were gradually increasing to 6, 19, 33,
56 and 67 μg/l at the onset and during the first two years
of therapy.
Laboratory methods
The study was approved by the local ethics committees
and all analyses were performed after proper informed
consent. Karyotyping of the patients was performed
using standard methods. Array comparative genomic
hybridization (CGH) used 180K and 105K CGH arrays
(Agilent Technologies) in Patient 1 and Patients 2/3, re-
spectively. The deletions were confirmed in the patients
and tested in the parents using fluorescence in situ
hybridization (FISH) with probes RP11-533L7/RP11-
550 M19 and RP11-550M19 (BlueGnome) in Patients 1
and 2, respectively. In Patient 3 the deletion was con-
firmed using a 60K CGH array (Agilent Technologies).
Results
Karyotyping did not show chromosome abnormalities in
any of the three patients. Array CGH revealed interstitial de-
letions of 14q22q23 of varying size (Figure 2) in the absence
of additional relevant submicroscopic aberrations. Patient 1
carried an 8.8 Mb long deletion (chr14:50293781–y deletions in the patients. The deletions in our patients are shown
lished cases as dotted bars. Intragenic deletions in OTX2 or BMP4
X2 or BMP4 are in red). The chromosome 14 banding pattern and
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BMP4 and OTX2 but not the SIX gene cluster. Patient 2
had a deletion of 8.9 Mb (chr14:54251697–63177878)
affecting OTX2 and the SIX gene cluster. Patient 3 had a
5.8 Mb long deletion (chr14:54431790–60167626) remov-
ing OTX2 and a part of the SIX gene cluster. Using inde-
pendent methods, all deletions were confirmed in the
patients but not in any of the parents, thus indicating the
de novo nature of the aberrations.Discussion
We present a case series of three patients with bilateral
anophthalmia caused by microdeletions of 14q22q23.
Their phenotype was further characterized by hearing
impairment, abnormal pituitary development leading to
GH deficiency and early growth failure, and dysmorphic
facial features. The overview of phenotypes observed in
published cases with 14q22q23 deletions and in our
three patients is in Table 1.
The 14q22q23 region is critical for eye and pituitary
development. Anophthalmia and other ocular anomalies
were associated with heterozygous defects in OTX2
[3,8,9] or BMP4 [7,10,11], and also with deletions involv-
ing both these genes [4,6,12]. While OTX2 was deleted
in all our patients, BMP4 was deleted only in Patient 1
(Figure 2). Nevertheless, the ocular phenotype was simi-
lar in all three children. The phenotypic effect of OTX2
and BMP4 disruptions is very variable ranging between
anophthalmia/microphthalmia, corneal opacity and no
abnormality at all, even in family members with the
same mutation [2,5,9-13], and the phenotype does not
have to be more severe in patients with combined
OTX2/BMP4 defects [4,12]. Patients 2 and 3 also lacked
SIX6; however, defects of this candidate gene have not
been identified in anophthalmia [1].
All three patients suffered from transient partial con-
ductive hearing loss. Previous reports of patients with
14q22q23 deletions were inconsistent, varying from not
mentioning the hearing status over normal function
[7,12] to severe unilateral hearing loss [4,9], indicating
very variable expressivity. We speculate that skeletal ab-
normalities of the facial-cranial junction of the skull as-
sociated with anophthalmia due to the OTX2 defect can
induce stenosis of ear canals and/or Eustachian tubes
and hearing impairment. Changing proportions of these
structures during growth could also explain the gradual
improvement of hearing with age observed in our pa-
tients. Interestingly, Patient 2 with large low-set dysplas-
tic ears was the only our patient with SIX1 disruption.
Homozygous knockout of this gene in mice causes mal-
formations of the auditory system including outer ears
[14]. Deletions in two published patients also involved
SIX1 and were associated with malformed ears, althoughdifferently from Patient 2 [4,9]. OTX2 defects themselves
could also contribute to ear anomalies [15].
Our patients showed abnormal pituitary development,
GH deficiency and growth retardation. Normal birth pa-
rameters and postnatal growth failure similar to that in
Patients 1 and 2 were reported in some cases with
14q22q23 deletions [3,4,11,12]. On the other hand, Pa-
tient 3 suffered from severe intrauterine growth retard-
ation without postnatal catch-up. An improvement of
growth was evident after GH therapy in all our patients
although the response varied. In Patients 1 and 3 the
therapy induced an increase of growth velocity and im-
provement of their height, whereas in Patient 2 it just
prevented further growth deterioration. However, in Pa-
tient 2 the growth failure was least pronounced with
height of −1.8 SD at the start of the GH therapy, and
this fact could influence the GH response. Similarly, two
published 14q22q23 deletion patients treated with GH
remained with their height at −2 SD after five and three
years of therapy [4,13], and the height of a boy with a
missense OTX2 mutation remained at −2.3 SD after
eight years of therapy [2]. As no reports are currently
available on final height of 14q22q23 deletion patients, it
remains to be seen if Patients 1 and 3 correct their
growth failure completely or if they just reach the
current height range of Patient 2. Differences in the de-
leted genes do not offer an obvious explanation for the
differences in responsiveness to the GH therapy. Two
genes involved in pituitary development, OTX2 and SIX6,
were disrupted in Patients 2 and 3. Patient 1 had a dele-
tion of OTX2 and BMP4, but not of SIX6. The differences
in pituitary morphology between Patient 1 and Patients 2
and 3 can also be attributed solely to the variability seen
among carriers of isolated OTX2 defects [1,3].
Finally, polydactyly was present in Patient 1 with a de-
letion of BMP4. This gene plays an important role in the
onset of endochondral bone formation in humans, and
its mutations were associated with polysyndactyly [4,11].
Recently, two papers were published describing pa-
tients with deletions overlapping the proximal and distal
part of the 14q22q23 region [16,17]. A family with Frias
syndrome carried a deletion of 14q22.1q22.3 spanning
the interval between GNG2 and KTN1, with BMP4 hap-
loinsufficiency being likely responsible for the phenotype
which included hypoplasia of corpus callosum, minor
ocular anomalies, specific tooth defects, digit anomalies,
short stature and intellectual impairment [16]. The other
deletion involving 14q22.3q23.2 and extending from
PSMA3 over the SIX cluster to SYNE2 was identified in
a patient with facial dysmorphism, choanal atresia,
esophageal reflux, defects of hands and feet, seizures and
intellectual disability [17]. Interestingly, in the latter case
neither microphthalmia/anophthalmia nor pituitary anom-
alies were present (MRI was normal), and neither OTX2



































Patient no. 1 1 1 2 1 2 5 1 3 I-1 II-2 III-5 III-6 1 1 1 2 3
14q deletion q22.1 q22.1 q22.3 q22.2 q22.2 q22.3 q22.3 q22.1 q22.2 q22.1 q22.1 q22.1 q22.1 q22.3 q22.2 q22.1 q22.3 q22.3
q23.1 q23.1 q23.2 q23.1 q22.3 q23.1 q23.1 q22.2 q23.1 q22.2 q22.2 q22.2 q22.2 q23.1 q23.1 q23.1 q23.2 q23.1
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GHD N.D. HT# - N.D. N.D. GHD N.D. N.D. N.D. N.D. - N.D. - - GHD GHD GHD
Prenatal growth Normal Normal N.D. N.D. Normal Normal Normal Normal N.D. Normal Normal Retarded Retarded Normal Normal Normal Normal Retarded
Postnatal growth Retarded Retarded N.D. N. D. N.D. N.D. Retarded Retarded N.D. Normal Retarded Retarded Retarded N.A.* Normal Retarded Retarded Retarded
Microcephaly + - - + - - + - + - - - + + - - + -
Hearing loss/
ear anomalies
+ - - + - - N.D. - - - - + - + - + + +
Undescended
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Table 1 Clinical features in eighteen patients with 14q22q23 deletions (Continued)
Polydactyly/
syndactyly












N.D., not described; N.A., not applicable; *patient too young; #not specified if secondary (central) or primary (peripheral).
Similarly to Figure 2, this table does not list patients with deletions assessed using karyotyping in whom the genes affected are uncertain and small deletions affecting only OTX2 or BMP4 exons. The deletions in
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intra- and interfamilial variability which, together with
biased and incomplete reporting of the phenotypes, com-
plicates the genotype-phenotype correlation in patients
with unique deletions affecting multiple genes which par-
ticipate in different molecular pathways [16,17].
Conclusions
Our case series study of three patients with deletions of
14q22q23 demonstrated the phenotypic features and
variable expressivity of this genetic defect. Comparison
with previously published patients with similar microde-
letions and mutations in the OTX2 gene suggests that
most symptoms presented by affected patients could be
attributed to OTX2 haploinsufficiency. Growth retard-
ation due to GH deficiency is very remarkable in these
patients and GH treatment can increase the growth vel-
ocity especially in the most severe cases but the response
can be atypical. The hearing impairment can be transient
and improves with age.
Consent
Written informed consent was obtained from the parents
of the patients for publication of this report and the ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SB, ZSl, PD, ABS, CM, LT and MG carried out the cytogenetic and molecular
cytogenetic studies; JL, ZSu, MS, EZ, SB, CM, KM and PL participated in the
analysis of the phenotype and genetic counseling; PD, ZSe, JL and SB
drafted the manuscript; ZSu edited the manuscript; ZSe, JL and GT
conceived, designed and coordinated the study. All authors read and
approved the final manuscript.
Acknowledgments
We thank the families for their cooperation. This work was supported by
Direction de l’Hospitalisation et de l’Organisation des Soins, grants NT13692
and DRO UH Motol 00064203 from the Czech Ministry of Health, and
CZ.2.16/3.1.00/24022.
Author details
1AP-HP, Service d’Histologie Embryologie et Cytogénétique, Hôpital Antoine
Béclère, Clamart, France. 2Department of Biology and Medical Genetics,
Charles University 2nd Faculty of Medicine and University Hospital Motol,
Prague, Czech Republic. 3Department of Pediatrics, Charles University 2nd
Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
4AP-HP, Service de Biochimie-Génétique, Plateforme de Génétique
Constitutionnelle, Hôpital Henri Mondor, Créteil, France. 5AP-HP, Service de
Pédiatrie, Hôpital Antoine Béclère, Clamart, France. 6Genetic and Pediatric
Ambulance, Benesov, Czech Republic. 7INSERM U935, Villejuif, France.
8Université Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre,
France. 9INSERM U955, Université Paris 12, Créteil, France.
Received: 10 December 2013 Accepted: 18 February 2014
Published: 28 February 2014
References
1. Slavotinek AM: Eye development genes and known syndromes. Mol Genet
Metab 2011, 104:448–456.2. Ashkenazi-Hoffnung L, Lebenthal Y, Wyatt AW, Ragge NK, Dateki S, Fukami
M, Ogata T, Phillip M, Gat-Yablonski G: A novel loss-of-function mutation
in OTX2 in a patient with anophthalmia and isolated growth hormone
deficiency. Hum Genet 2010, 127:721–729.
3. Dateki S, Kosaka K, Hasegawa K, Tanaka H, Azuma N, Yokoya S, Muroya K,
Adachi M, Tajima T, Motomura K, Kinoshita E, Moriuchi H, Sato N, Fukami M,
Ogata T: Heterozygous orthodenticle homeobox 2 mutations are
associated with variable pituitary phenotype. J Clin Endocrinol Metab
2010, 95:756–764.
4. Nolen LD, Amor D, Haywood A, St Heaps L, Willcock C, Mihelec M, Tam P,
Billson F, Grigg J, Peters G, Jamieson RV: Deletion at 14q22-23 indicates a
contiguous gene syndrome comprising anophthalmia, pituitary
hypoplasia, and ear anomalies. Am J Med Genet A 2006, 140:1711–1718.
5. Schilter KF, Schneider A, Bardakjian T, Soucy JF, Tyler RC, Reis LM, Semina
EV: OTX2 microphthalmia syndrome: four novel mutations and
delineation of a phenotype. Clin Genet 2011, 79:158–168.
6. Bakrania P, Efthymiou M, Klein JC, Salt A, Bunyan DJ, Wyatt A, Ponting CP,
Martin A, Williams S, Lindley V, Gilmore J, Restori M, Robson AG, Neveu MM,
Holder GE, Collin JR, Robinson DO, Farndon P, Johansen-Berg H, Gerrelli D,
Ragge NK: Mutations in BMP4 cause eye, brain, and digit developmental
anomalies: overlap between the BMP4 and hedgehog signaling
pathways. Am J Hum Genet 2008, 82:304–319.
7. Reis LM, Tyler RC, Schilter KF, Abdul-Rahman O, Innis JW, Kozel BA,
Schneider AS, Bardakjian TM, Lose EJ, Martin DM, Broeckel U, Semina EV:
BMP4 loss-of-function mutations in developmental eye disorders includ-
ing SHORT syndrome. Hum Genet 2011, 130:495–504.
8. Wyatt A, Bakrania P, Bunyan DJ, Osborne RJ, Crolla JA, Salt A, Ayuso C,
Newbury-Ecob R, Abou-Rayyah Y, Collin JR, Robinson D, Ragge N: Novel
heterozygous OTX2 mutations and whole gene deletions in anophthal-
mia, microphthalmia and coloboma. Hum Mutat 2008, 29:E278–E283.
9. Pearce ZD, Droste PJ, Aaberg TM Jr, Hassan AS: Ophthalmic and systemic
findings in interstitial deletions of chromosome 14q: a case report and
literature review. Ophthalmic Genet 2012, 33:161–166.
10. Lumaka A, Van Hole C, Casteels I, Ortibus E, De Wolf V, Vermeesch JR,
Lukusa T, Devriendt K: Variability in expression of a familial 2.79 Mb
microdeletion in chromosome 14q22.1-22.2. Am J Med Genet A 2012,
158A:1381–1387.
11. Hayashi S, Okamoto N, Makita Y, Hata A, Imoto I, Inazawa J: Heterozygous
deletion at 14q22.1-q22.3 including the BMP4 gene in a patient with
psychomotor retardation, congenital corneal opacity and feet
polysyndactyly. Am J Med Genet A 2008, 146A:2905–2910.
12. Takenouchi T, Nishina S, Kosaki R, Torii C, Furukawa R, Takahashi T, Kosaki K:
Concurrent deletion of BMP4 and OTX2 genes, two master genes in
ophthalmogenesis. Eur J Med Genet 2013, 56:50–53.
13. Delahaye A, Bitoun P, Drunat S, Gerard-Blanluet M, Chassaing N, Toutain A,
Verloes A, Gatelais F, Legendre M, Faivre L, Passemard S, Aboura A, Kaltenbach S,
Quentin S, Dupont C, Tabet AC, Amselem S, Elion J, Gressens P, Pipiras E,
Benzacken B: Genomic imbalances detected by array-CGH in patients with
syndromal ocular developmental anomalies. Eur J Hum Genet 2012, 20:527–533.
14. Zheng W, Huang L, Wei ZB, Silvius D, Tang B, Xu PX: The role of Six1 in
mammalian auditory system development. Development 2003,
130:3989–4000.
15. Chassaing N, Sorrentino S, Davis EE, Martin-Coignard D, Iacovelli A, Paznekas W,
Webb BD, Faye-Petersen O, Encha-Razavi F, Lequeux L, Vigouroux A, Yesilyurt A,
Boyadjiev SA, Kayserili H, Loget P, Carles D, Sergi C, Puvabanditsin S, Chen CP,
Etchevers HC, Katsanis N, Mercer CL, Calvas P, Jabs EW: OTX2 mutations con-
tribute to the otocephaly-dysgnathia complex. J Med Genet 2012, 49:373–379.
16. Martinez-Fernandez ML, Bermejo-Sanchez E, Fernandez B, Macdonald A,
Fernandez-Toral J, Martinez-Frias ML: Haploinsufficiency of BMP4 gene
may be the underlying cause of Frias syndrome. Am J Med Genet A 2014,
164:338–345.
17. Martinez-Frias ML, Ocejo-Vinyals JG, Arteaga R, Martinez-Fernandez ML,
Macdonald A, Perez-Belmonte E, Bermejo-Sanchez E, Martinez S: Interstitial
deletion 14q22.3-q23.2: genotype-phenotype correlation. Am J Med Genet
A 2014. in press.
doi:10.1186/1755-8166-7-17
Cite this article as: Brisset et al.: Anophthalmia, hearing loss, abnormal
pituitary development and response to growth hormone therapy in
three children with microdeletions of 14q22q23. Molecular Cytogenetics
2014 7:17.
